Model of experimental nonalcoholic steatohepatitis from use of methionine and choline deficient diet;Modelo experimental de esteatohepatite não-alcoólica com dieta deficiente em metionina e colina

Arquivos de Gastroenterologia

Volumn 46, Issue 1, 2009, Pages 69-74

  Zamin Jr , Idilio ^a,b   De Mattos, Angelo Alves ^a   De Mattos, Ângelo Zambam ^a   Migon, Eduardo ^a   Soares, Ernsto ^a   Perry, Marcos Luiz Santos ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b Rua Armando Pereira Câmara 111 apt 801 ^*  (Brazil)

Author keywords

Choline deficiency; Diet; Fatty liver; Methionine, deficiency; Rats

Indexed keywords

CHOLINE; METHIONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DECAPITATION; EXPERIMENTAL MODEL; HISTOLOGY; LAPAROTOMY; LIVER RESECTION; MALE; MALNUTRITION; MICROSCOPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT; VITAMIN DEFICIENCY; WISTAR RAT;

ANIMAL FEED; ANIMALS; CHOLINE DEFICIENCY; DISEASE MODELS, ANIMAL; FATTY LIVER; LIVER; MALE; METHIONINE; RATS; RATS, WISTAR;

EID: 66449135397     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032009000100017     Document Type: Article

References (56)

1. Altman Dg. Practical statistics for medical research. London: Chapman & Hall; 1991. 611 p.
2. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1702-1704 (Pubitemid 35231669)
3. Anderson T, Gluud C, Franzmann Mb. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12:224-229
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231
5. Bacon Br, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an explanded clinical entity. Gastroenterology. 1994;107:1103-1109 (Pubitemid 24294573)
6. Baffy G, Zhang CY, Glickman JN, Lowell BB. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology. 2002;35:753-761 (Pubitemid 34258368)
7. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon B. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474 (Pubitemid 29420675)
8. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-140 (Pubitemid 34747534)
9. Caldwell Sh, Oelsner DH, Iezzoni JC. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-669 (Pubitemid 29109578)
10. Caldwell Sh, Hespenheide EE, Redick JA, Tezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519-525 (Pubitemid 32184944)
11. Capron Jp, Delamarre J, Dupas JL, Braillon A, Degott C, Quenum C. Fasting in obesity: another cause of liver injury with alcoholic hyaline? Dig Dis Sci. 1982;27:265-268
12. Clark Jm, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649-1657 (Pubitemid 34533559)
13. Diehl Am, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 1988;95:1056-1062
14. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand. 1986;220:83-88 (Pubitemid 16041850)
15. Grattagliano I, Vandemiale G, Caraceni P, Domenicali M, Nardo B, Cavallari A, Trevisani F, Bernardi M, Altomare E. Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet. J Nutr. 2000;130:2131-2136
16. Harrison sA, Torgenson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485-2490
17. Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2004;8:861-879 (Pubitemid 39311147)
18. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002;122:1399-1410 (Pubitemid 34465182)
19. Kakuma T, Lee Y, Higa M., Wang Z, Pan W, Shimomura I, Unger RH. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci. 2000;97:8536-8541 (Pubitemid 30639708)
20. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis. 2001;21:89-104. (Pubitemid 32240489)
21. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413-419 (Pubitemid 36919862)
22. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464-1467 (Pubitemid 26181230)
23. Lavineje Je. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734-738 (Pubitemid 30415645)
24. Leclerq Ia, Farrel GC, Field J, Bell DR, Gonzales FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067-1075 (Pubitemid 30217691)
25. Lee Rg. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20:594-598 (Pubitemid 19164370)
26. Lettéron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol. 1996;24:200-208 (Pubitemid 26059117)
27. Lieber Cs, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM. Model of non-alcoholic steatohepatitis. Am J Clin Nutr. 2004;79:502-509
28. Lin Hz, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998-1003.
29. Lindor KD, Kowdley KV, Heatchcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgat L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770-778 (Pubitemid 38337657)
30. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438
31. Ludwig J, McGill DB, Lindor KD. Review: Nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 1997;12:398-403. (Pubitemid 27244505)
32. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419 (Pubitemid 29258890)
33. Marchesini G, Brizi M, Bianchi G. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893-894 (Pubitemid 32900577)
34. Montgomery DC. Design and analysis of experiments. New York: John Wiley; 1984. 538 p.
35. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon B. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-y ligant rosiglitazone. Hepatology. 2003;38:1008-1017 (Pubitemid 37221684)
36. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-1219 (Pubitemid 36538699)
37. Okan A, Astarcioglu H, Tankurt, Sagol O, Altekin E, Astarcioglu I, Gonen O. Effect of ursodeoxycholic acid on hepatic steatosis in rats. Dig Dis Sci. 2002;47:2389-2397 (Pubitemid 35305441)
38. Palmer M, Schaffener F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408-1413 (Pubitemid 20381878)
39. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:540-543
40. Pessayre D, Berson A, Beco VD. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998;114:764-774 (Pubitemid 28160411)
41. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CT, Hess JF. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet. 1996;13:18-19
42. Poulsom R. Morphological changes of organs after sucrose or fructose feeding. Prog Biochem Pharmacol. 1986;21:104-134
43. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell L. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80. (Pubitemid 20075105)
44. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117-1123 (Pubitemid 30346988)
45. Rogers AE, Newberne PM. Alcoholic and nutritional fatty liver and cirrhosis. Am J Pathol. 1973;73:817-820
46. Saviano MC, Brunetti F, Rubino A, Franzase A, Vajro P, Argenziano A, Puzziello A, Iannucci MP. Liver involvement obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997;42:1428-1432 (Pubitemid 27339358)
47. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ ob mice. Hepatology. 2002;35:762-771 (Pubitemid 34258369)
48. Schaffner F, Adler M. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979;67:811-816 (Pubitemid 10218835)
49. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283-298
50. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018-1022 (Pubitemid 29173621)
51. Teli MR, James OFW, Burt AD, Bennett MK, Day C. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714-1719
52. Wang RT, Koretz RL, Yee HF. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med. 2003;115:554-559 (Pubitemid 37352802)
53. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106-1110
54. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996;111:1645-1653 (Pubitemid 26404230)
55. Younossi Z, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35:746-752 (Pubitemid 34258367)
56. Zamin IJ, Mattos AA, Zettler CG. Non-alcoholic steatohepatitis in nondiabetic obese patients. Can J Gastroenterol. 2002;16:303-308